GlobeNewswire: Amydis, Inc. Contains the last 10 of 24 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:42:06ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/11/14/2779892/0/en/Amydis-Receives-3-4-million-NIH-Commercialization-Readiness-Pilot-Grant-Award-to-Map-Heterogeneity-of-Alzheimer-s-Diseases-in-Human-Clinical-Trial-Using-Novel-Retinal-Tracer.html?f=22&fvtc=4&fvtv=27237Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer2023-11-14T12:00:00Z<![CDATA[Amydis Novel Tracer Utilizes an Affordable, Accessible, Non-Invasive Approach as part of a Standard Office Visit Amydis Novel Tracer Utilizes an Affordable, Accessible, Non-Invasive Approach as part of a Standard Office Visit]]>https://www.globenewswire.com/news-release/2023/11/02/2772102/0/en/Amydis-Launches-Phase-2-Glaucoma-Clinical-Program-Using-Novel-Retinal-Tracer-to-Detect-Amyloid-Beta.html?f=22&fvtc=4&fvtv=27237Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta2023-11-02T11:00:00Z<![CDATA[Glaucoma is leading cause of irreversible blindness worldwide, projected to affect 112 million people by 2040 Glaucoma is leading cause of irreversible blindness worldwide, projected to affect 112 million people by 2040]]>https://www.globenewswire.com/news-release/2023/02/21/2611806/0/en/Amydis-Announces-Enrollment-of-Cerebral-Amyloid-Angiopathy-Participants-in-Phase-1-2a-Retinal-Tracer-Trial.html?f=22&fvtc=4&fvtv=27237Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial2023-02-21T10:00:00Z<![CDATA[SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease biomarkers in the eye, today announced initiation of enrollment of patients with cerebral amyloid angiopathy (CAA), an age-associated disease in which a protein called amyloid beta (Aβ) builds up on the walls of the arteries in the brain increasing the risk for stroke and dementia. CAA develops in up to 23% of the general population with aging, and it occurs at a higher rate of ~48% in people with Alzheimer’s disease due to overlapping etiology. The Randomized Open, Blinded Endpoint Phase 1/2a trial funded in part by a $3 million commercialization readiness pilot grant from the National Institute of Aging at National Institutes of Health (NIH) is evaluating the safety, tolerability, pharmacokinetics, and activity of AMDX-2011P, a proprietary small molecule ocular imaging agent targeting deposits of Aβ in the retina of patients with CAA. This trial (NCT05709314) is part of a larger “basket trial” that also includes a study (NCT05542576) evaluating Amydis ocular tracer technology in amyotrophic later sclerosis and Parkinson’s disease. These studies are being conducted at two sites in Southern California. Additional information regarding the clinical trial, may be found at https://probeclinicaltrial.com/home .]]>https://www.globenewswire.com/news-release/2022/10/27/2542649/0/en/Amydis-Awarded-Third-Grant-From-The-Michael-J-Fox-Foundation-To-Support-First-In-Human-Study-of-a-Retinal-Tracer-for-Parkinson-s-Disease.html?f=22&fvtc=4&fvtv=27237Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease2022-10-27T11:00:00Z<![CDATA[SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting molecular biomarkers in the eye, today announced it has been awarded a third grant for $1.5M from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will support the first-in-human study of a retinal tracer targeting alpha-synuclein (ASYN) in a Prospective Randomized Open, Blinded Endpoint (PROBE) clinical study which is currently enrolling participants. Additional information regarding the Phase 1/2a trial (NCT05542576) may be found at Fox Trial Finder.]]>https://www.globenewswire.com/news-release/2022/09/22/2520861/0/en/Amydis-Announces-Enrollment-of-First-Participants-in-PROBE-a-Phase-1-2a-Trial-Evaluating-a-Novel-Retinal-Tracer-in-People-with-Amyotrophic-Lateral-Sclerosis-or-Parkinson-s-Disease.html?f=22&fvtc=4&fvtv=27237Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease2022-09-22T11:00:00Z<![CDATA[SAN DIEGO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced dosing of the first patients in the company’s Phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of alpha synuclein (ASYN) and the TAR DNA-binding protein 43 (TDP-43) in patients with Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS), respectively.]]>https://www.globenewswire.com/news-release/2022/08/18/2500670/0/en/Amydis-Receives-NIH-Grant-Award-to-Develop-a-Novel-TDP-43-Retinal-Tracer-in-Patients-with-ALS-and-FTD.html?f=22&fvtc=4&fvtv=27237Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients with ALS and FTD2022-08-18T11:00:00Z<![CDATA[SAN DIEGO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH). The grant supports the development of a novel small-molecule retinal tracer targeting the biomarker TAR DNA-binding protein 43 (TDP-43) in patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).]]>https://www.globenewswire.com/news-release/2022/04/04/2415577/0/en/Amydis-Appoints-Dr-Robert-N-Weinreb-as-First-Chair-of-Scientific-Advisory-Board.html?f=22&fvtc=4&fvtv=27237Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board2022-04-04T11:00:00Z<![CDATA[SAN DIEGO, April 04, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a healthcare company developing a new class of molecular retinal diagnostics and digital biomarkers to accelerate the early detection and monitoring of neurodegenerative diseases, today announced the appointment of internationally recognized clinician scientist, Robert N. Weinreb M.D. as the First Chair to the Scientific Advisory Board of the Company.]]>https://www.globenewswire.com/news-release/2021/12/06/2346402/0/en/Amydis-Announces-Successful-Completion-of-a-Pre-IND-Meeting-with-the-FDA-for-the-Development-of-a-First-in-Class-Retinal-Tracer-Targeting-TDP43-for-the-Diagnosis-of-ALS.html?f=22&fvtc=4&fvtv=27237Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS2021-12-06T12:00:00Z<![CDATA[SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a biotechnology company developing novel ocular contrast agents (“tracers”) targeting CNS biomarkers in the eye, today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plans for a small-molecule tracer to detect TDP43 in the retina of amyotrophic lateral sclerosis (ALS) patients. The FDA agreed with the overall design of the proposed Phase 1/2a first-in-human clinical study in ALS patients. Amydis is planning to initiate the clinical trial by first half of 2022. The design of the planned study may allow for an early read-out on the potential ability of the retinal tracer to aid in the diagnosis and management of patients with ALS.]]>https://www.globenewswire.com/news-release/2021/10/11/2311704/0/en/Amydis-Awarded-3-Million-NIH-Grant-to-Explore-Novel-Alpha-Synuclein-Retinal-Tracer-in-Non-human-Primate-Models-of-Parkinson-s-Disease-and-Multiple-System-Atrophy.html?f=22&fvtc=4&fvtv=27237Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy2021-10-11T11:00:00Z<![CDATA[SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a grant award of $3 million from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH). The two-year award will explore the presence of alpha synuclein (ASYN) in the retina of non-human primate models of Parkinson’s Disease (PD) and Multiple System Atrophy (MSA). With the support of two grant awards from the Michael J. Fox Foundation, Amydis has previously shown that its proprietary retinal tracers can detect ASYN in PD mouse models. This NIH grant will also fund Investigational New Drug Application (IND)-enabling studies to support an IND filing with the Food & Drug Administration (FDA). Earlier this year, Amydis completed a pre-IND meeting with the FDA and obtained agreement on the design of a first-in-human Phase 1/2a clinical trial to be conducted in patients and healthy volunteers. The planned Phase 1/2a clinical study will test Amydis’s small-molecule retinal tracer targeting the biomarker ASYN for the diagnosis of synucleinopathies.]]>https://www.globenewswire.com/news-release/2021/09/02/2290749/0/en/Amydis-Receives-NIH-Grant-Award-to-Develop-a-Novel-Tau-Retinal-Tracer-for-Alzheimer-s-Diseases-and-other-Tauopathies.html?f=22&fvtc=4&fvtv=27237Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer's Diseases and other Tauopathies2021-09-02T11:00:00Z<![CDATA[SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH). The grant will support the development of a novel small-molecule retinal tracer targeting the biomarker tau for the detection and diagnosis of Alzheimer’s disease and other tauopathies.]]>